Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -27.34% and Operating profit at -172.21% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Negative results in Sep 26
Risky - Negative EBITDA
44.88% of Promoter Shares are Pledged
Stock DNA
Pharmaceuticals & Biotechnology
INR 49 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
1.77
-26.78%
1.05
Total Returns (Price + Dividend) 
Latest dividend: 0.8 per share ex-dividend date: Nov-02-2021
Risk Adjusted Returns v/s 
Returns Beta
News

ANG Lifesciences India Ltd Downgraded to Strong Sell Amid Weak Financials and Mixed Technicals
ANG Lifesciences India Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 23 Oct 2026, reflecting deteriorating financial fundamentals and a complex technical outlook. Despite some mildly bullish technical signals, the company’s weak profitability, high debt burden, and negative operating performance have weighed heavily on investor sentiment, leading to a significant reassessment of its prospects.
Read More
ANG Lifesciences India Ltd Upgraded to Sell Amid Mixed Technical and Financial Signals
ANG Lifesciences India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 Oct 2026, driven primarily by improved technical indicators despite ongoing financial challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, reflecting a shift in market sentiment, although fundamental weaknesses and valuation concerns persist.
Read More
ANG Lifesciences India Ltd is Rated Strong Sell
ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 21 October 2026, providing investors with the latest comprehensive view.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Change in Management
18-Nov-2026 | Source : BSECessation of Independent Director upon completion of tenure.
Announcement under Regulation 30 (LODR)-Change in Management
14-Nov-2026 | Source : BSEAppointment of Mrs. Preeti Sarin as Additional Independent Director of the Company
Financial Results For The Quarter And Half Year Ended 30.09.2026.
14-Nov-2026 | Source : BSEFinancial Results for the quarter and half year ended 30.09.2026.
Corporate Actions 
No Upcoming Board Meetings
ANG Lifesciences India Ltd has declared 10% dividend, ex-date: 02 Nov 21
No Splits history available
ANG Lifesciences India Ltd has announced 1:4 bonus issue, ex-date: 13 Jul 22
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
44.8775
Held by 0 Schemes
Held by 0 FIIs
Rajesh Gupta (70.41%)
None
26.42%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is -22.84% vs -20.77% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 29.15% vs -41.15% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -1.23% vs -42.83% in Sep 2024
Growth in half year ended Sep 2025 is 4.07% vs -805.26% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -8.72% vs -29.79% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 6.28% vs -59.23% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 0.04% vs -36.45% in Mar 2025
YoY Growth in year ended Mar 2026 is 10.72% vs -22.39% in Mar 2025